(Press-News.org) PHILADELPHIA – The American Association for Cancer Research (AACR) will award Olivier Delattre, MD, PhD, with the 2023 AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research during the AACR Annual Meeting 2023, April 14-19 at the Orange County Convention Center in Orlando, Florida.
Delattre is the director of the SIREDO Oncology Center and the research unit director of the Cancer, Heterogeneity, Instability and Plasticity (CHIP) unit at Inserm/Institut Curie. He is being recognized for a series of seminal genetic insights into the etiology of pediatric solid tumors that have had substantial clinical implications.
The AACR and the St. Baldrick’s Foundation established the AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer in 2019 to bring attention to major pediatric cancer research discoveries and to honor individuals who have significantly contributed to any area of pediatric cancer research, resulting in the fundamental improvement of the understanding and/or treatment of pediatric cancer.
Delattre is internationally heralded for having transformed the field of pediatric cancer research by opening new avenues for pediatric cancer screening, while improving the precision of molecular diagnostics. He was the first to report the molecular characterization of the EWS-FLI1 chromosomal translocation in Ewing sarcoma, which is now central to the accurate diagnosis of that cancer. He has also been instrumental in identifying genetic alterations in other childhood cancers, including the BCOR-CCNB3 translocation in Ewing-like sarcoma and ALK mutations in neuroblastoma and other EWS-translocation-positive sarcomas. He was one of the first to demonstrate the existence of mutations within chromatin remodeling complexes in cancer, which are now known to occur in approximately 20% of human cancers. Delattre’s work has been crucial to identifying major cancer predisposition genes for neurofibromatosis type 2, neuroblastoma, and a rhabdoid tumor predisposition syndrome, generating new insights into pediatric cancer susceptibility.
Delattre has been a leader in developing genetically engineered mouse models for neuroblastoma and rhabdoid tumors. These models have been used to evaluate candidate drug targets, assess therapeutic efficacy, and investigate drug resistance mechanisms. He has explored the oncogenic plasticity of pediatric cancers, furthering our understanding of the development of pediatric solid tumors. More recently, his work has focused on the identification of tumor-specific neogenes driven by chimeric transcription factors in sarcoma, work that has the potential to establish innovative avenues for the development of new therapeutic approaches for pediatric cancer.
Delattre has been an AACR member since 2015. He joined the AACR’s Pediatric Cancer Working Group (PCWG) in 2013 and has served on the AACR-PCWG Steering Committee since 2020. He has served as a member of the AACR-Aflac Inc. Career Development Award for Pediatric Cancer Research Scientific Review Committee (2016-2018); member of the AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research Committee (2019-2020); and member of the AACR Pediatric Cancer Research Grants Scientific Review Committee (2019-2021).
Delattre’s work has been recognized with many awards and honors, such as the Inserm Grand Prix (2022), the Jeremy Jass Prize for Research Excellence in Pathology (2019), The Fondation ARC Léopold Griffuel Award (2016), the CTOS Herman Suit Special Award Lecture (2014), the Charles Oberling Award (2009), the EUROCANCER Award (2007), the Award of the Académie Nationale de Médecine (2000), the Gaston Rousseau Award of Académie des Sciences (1996), the Olga Sain Award of Comité de Paris of the Ligue Nationale Contre le Cancer (1995), the Fondation pour la Recherche Médicale Rose Lamarca Award of Clinical Investigation (1995), the EURE Award of the Ligue Nationale Contre le Cancer (1993), and the Jacques Sylvain Bourdin Award of Comité de l'Essonne of the Ligue Nationale Contre le Cancer (1993). He was elected as a member of the Academia Europea (2012) and the European Molecular Biology Organization (2011).
Delattre received his medical degree from Pierre and Marie Curie University and earned his PhD in molecular biology from Paris Diderot University in France.
Delattre’s award lecture, titled “Ewing sarcoma, a paradigm for cell reprogramming in cancer,” will be held on Tuesday, April 18 at 5 p.m. ET at the Orange County Convention Center.
END
Olivier Delattre, MD, Ph.D., honored with 2023 AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research
2023-03-29
ELSE PRESS RELEASES FROM THIS DATE:
SwRI’s NASGRO software selected for Space Technology Hall of Fame
2023-03-29
SAN ANTONIO — March 29, 2023 —The NASGRO® software suite will be inducted into the Space Technology Hall of Fame alongside the leaders of its development team, Southwest Research Institute’s Dr. Craig McClung and Joe Cardinal, as well as Joachim Beek of NASA’s Johnson Space Center (JSC). The award ceremony will occur during the annual Space Symposium in Colorado Springs. NASGRO, originally developed by NASA and currently managed by SwRI, analyzes fatigue crack growth and fracture in structures and mechanical components. It is a key tool used to substantiate the structural integrity of aircraft, spacecraft, rotorcraft, gas turbine engines, pressure ...
Study shows human brain can assist with computational ghost imaging
2023-03-29
Interacting with computers by brain activity seems less futuristic these days, thanks to researchers and entrepreneurs who have been attempting to tap the potential of brain-computer interfaces for augmented cognitive abilities. Recently, Gao Wang and Daniele Faccio at the University of Glasgow demonstrated that it is possible to connect a human brain and a computer to perform simple computational imaging tasks. Similar advances could someday extend the sensing range of human vision and provide new approaches to the neurophysics of human perception. This research was published Feb. 24 in Intelligent Computing, a Science Partner ...
COVID-19 during pregnancy may increase obesity risk in children
2023-03-29
WASHINGTON—Children born to mothers who had COVID-19 during pregnancy may be more likely to develop obesity, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
More than 100 million COVID-19 cases have been reported in the United States since 2019, and there is limited information on the long-term health effects of the infection. Pregnant women make up 9% of reproductive-aged women with COVID-19, and millions of babies will be exposed to maternal infection during ...
Advanced pancreatic cancer model for developing personalized therapies
2023-03-29
(LOS ANGELES) – March 28, 2023 - Pancreatic ductal adenocarcinoma (PDAC), is highly aggressive and lethal. It is the most prevalent type of pancreatic cancer, making up 90% of cases; it also has a high rate of metastasis, with an average five-year survival rate of less than 10%.
It is thought that the dense, stiff matrix immediately surrounding its tumor cells plays a major role in PDAC disease progression. In addition to influencing pancreatic tissue fibrosis, it also limits accessibility and effectiveness of anticancer drugs against the tumor and enhances the promotion of surface ...
Surgical sealing made better with robust thermosensitive bioadhesives
2023-03-29
(LOS ANGELES) – March 28, 2023 - As part of a collaborative effort, scientists from the Terasaki Institute for Biomedical Innovation (TIBI) have employed inventive chemistry to produce an injectable biomaterial with significantly improved adhesive strength, stretchability, and toughness. This chemically modified, gelatin-based hydrogel had attractive features, including rapid gelation at room temperature and tunable levels of adhesion. This custom-engineered biomaterial is ideal as a surgical wound sealant, with its controllable adhesion and injectability and its superior ...
Personalized gut microbiome analysis for colorectal cancer classification with explainable AI
2023-03-29
The gut microbiome comprises a complex population of different bacterial species that are essential to human health. In recent years, scientists across several fields have found that changes in the gut microbiome can be linked to a wide variety of diseases, notably colorectal cancer (CRC). Multiple studies have revealed that a higher abundance of certain bacteria, such as Fusobacterium nucleatum and Parvimonas micra, is typically associated with CRC progression.
Based on these findings, researchers have ...
Three newly discovered sea worms that glow in the dark named after creatures from Japanese folklore and marine biologist
2023-03-29
A research group from Nagoya University in central Japan has discovered three new species of bioluminescent polycirrus worms from different parts of Japan. Usually found in shallow water, polycirrus are small worms, known for their bioluminescence. The researchers named one of their discoveries after a ghostly yokai, a creature in Japanese foklore; another after a lantern yokai; and the other after an influential Japanese marine biologist. They published their findings in the journal Royal Society Open Science.
Scientists have studied only a small fraction of the more than 7,000 species of luminescent organisms in the world. Research remains limited to certain species because ...
The element of surprise: How unexpected syntax makes marketing communications more effective
2023-03-29
Researchers from Frankfurt School of Finance and Management published a new Journal of Marketing article that examines the role of syntactic surprise in formulating effective written messages.
The study, forthcoming in the Journal of Marketing, is titled “Creating Effective Marketing Messages Through Moderately Surprising Syntax” and is authored by A. Selin Atalay, Siham El Kihal, and Florian Ellsaesser.
Consider a manager advertising for a job, deciding whether to go with “Apply today to join a great ...
Hemex Health awarded $3M NIH grant to bring Gazelle Hb Variant Test for sickle cell disease to US market
2023-03-29
Portland, Ore. – March 27, 2023 – Hemex Health, a medical diagnostic device company focused on expanding healthcare access to underrepresented patient populations, announced it has been awarded a 3-year, $3 million grant from the National Heart, Lung, and Blood Institute (NHLBI). NHLBI, part of the National Institutes of Health, awarded a SBIR Phase IIB Bridge Award to Hemex to advance the commercialization of the company’s Gazelle® Hb Variant Test for the United States market.
Hemex intends to use the grant to complete activities required for FDA 510(k) clearance.
The Hb Variant Test, one of the tests supported ...
New virtual entrepreneurial training launches to support innovators addressing health equity
2023-03-29
DALLAS, March 29, 2023 — New training tools from the American Heart Association will help health equity innovators address issues like structural racism and other social factors that impact health in urban and rural communities. A recent study found that Black and LatinX founders represented just 2.6% of total funding raised by venture capital in 2020.[1] In its commitment to ensuring equitable health for all, the Association supports innovators and other social enterprises, start-ups, non-profits, and digital and health tech companies that are addressing health equity challenges in their local communities with mentoring, funding opportunities and – now – ongoing ...